Skip to main content
  1. Right Decisions
  2. Maternity & Gynaecology Guidelines
  3. Maternity
  4. Back
  5. Antenatal, general
  6. Monitoring and Management of Suspected Fetal Growth Restriction (414)
Important: please update your RDS app to version 4.7.3

Welcome to the March 2025 update from the RDS team

1.     RDS issues - resolutions

1.1 Stability issues - Tactuum implemented a fix on 24th March which we believe has finally addressed the stability issues experienced over recent weeks.  The issue seems to have been related to the new “Tool export” function making repeated calls for content when new toolkit nodes were opened in Umbraco. No outages have been reported since then, and no performance issues in the logs, so fingers crossed this is now resolved.

1.2 Toolkit URL redirects failing– these were restored manually for the antimicrobial calculators on the 13th March when the issue occurred, and by 15th March for the remainder. The root cause was traced to adding a new hostname for an app migrated from another health board and made live that day. This led to the content management system automatically creating internal duplicate redirects, reaching the maximum number of permitted redirects and most redirects therefore ceasing to function.

This issue should not happen again because:

  • All old apps are now fully migrated to RDS. The large number of migrations has contributed to the high number of automated redirects.
  • If there is any need to change hostnames in future, Tactuum will immediately check for duplicates.

1.3 Gentamicin calculators – Incidents have been reported incidents of people accessing the wrong gentamicin calculator for their health board.  This occurs when clinicians are searching for the gentamicin calculator via an online search engine - e.g. Google - rather than via the health board directed policy route. When accessed via an external search engine, the calculator results are not listed by health board, and the start page for the calculator does not make it clearly visible which health board calculator has been selected.

The Scottish Antimicrobial Prescribing Group has asked health boards to provide targeted communication and education to ensure that clinicians know how to access their health board antimicrobial calculators via the RDS, local Intranet or other local policy route. In terms of RDS amendments, it is not currently possible to change the internet search output, so the following changes are now in progress:

  • The health board name will now be displayed within the calculator and it will be made clear which boards are using the ‘Hartford’ (7mg/kg) higher dose calculator
  • Warning text will be added to the calculator to advise that more than one calculator is in use in NHS Scotland and that clinicians should ensure they access the correct one for their health board. A link to the Right Decision Service list of health board antimicrobial prescribing toolkits will be included with the warning text. Users can then access the correct calculator for their Board via the appropriate toolkit.

We would encourage all editors and users to use the Help and Support standard operating procedure and the Editors’ Teams channel to highlight issues, even if you think they may be temporary or already noted. This helps the RDS team to get a full picture of concerns and issues across the service.

 

2.     New RDS presentation – RDS supporting the patient journey

A new presentation illustrating how RDS supports all partners in the patient journey – multiple disciplines across secondary, primary, community and social care settings – as well as patients and carers through self-management and shared decision-making tools – is now available. You will find it in the Promotion and presentation resources for editors section of the Learning and support toolkit.

3.     User guides

A new user guide is now available in the Guidance and tips section of Resources for providers within the Learning and Support area, explaining how to embed content from Google Calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream and Jotforms into RDS pages. A webinar for editors on using this new functionality is scheduled for 1 May 3-4 pm (booking information below.)

A new checklist to support editors in making all the checks required before making a new toolkit live is now available at the foot of the “Request a new toolkit” standard operating procedure. Completing this checklist is not a mandatory part of the governance process, but we would encourage you to use it to make sure all the critical issues are covered at point of launch – including organisational tags, use of Alias URLs and editorial information.

4.Training sessions for RDS editors

Introductory webinars for RDS editors will take place on:

  • Tuesday 29th April 4-5 pm
  • Thursday 1st May 4-5 pm

Special webinar for RDS editors – 1 May 3-4 pm

This webinar will cover:

  1. a) Use of the new left hand navigation option for RDS toolkits.
  2. b) Integration into RDS pages of content from external sources, including Google Calendar, Google Maps and simple Jotforms calculators.

Running usage statistics reports using Google analytics

  • Wednesday 23rd April 2pm-3pm
  • Thursday 22nd May 2pm-3pm

To book a place on any of these webinars, please contact Olivia.graham@nhs.scot providing your name, role, organisation, title and date of the webinar you wish to attend.

5.New RDS toolkits

The following toolkits were launched during March 2025:

SIGN guideline - Prevention and remission of type 2 diabetes

Valproate – easy read version for people with learning disabilities (Scottish Government Medicines Division)

Obstetrics and gynaecology induction toolkit (NHS Lothian) – password-protected, in pilot stage.

Oral care for care home and care at home services (Public Health Scotland)

Postural care in care homes (NHS Lothian)

Quit Your Way Pregnancy Service (NHS GGC)

 

6.New RDS developments

Release of the redesign of RDS search and browse, archiving and version control functionality, and editing capability for shared content, is now provisionally scheduled for early June.

The Scottish Government Realistic Medicine Policy team is leading development of a national approach to implementation of Patient-Reported Outcome Measures (PROMs) as a key objective within the Value Based Health and Care Action Plan. The Right Decision Service has been commissioned to deliver an initial version of a platform for issuing PROMs questionnaires to patients, making the PROMs reports available from patient record systems, and providing an analytics dashboard to compare outcomes across services.  This work is now underway and we will keep you updated on progress.

The RDS team has supported Scottish Government Effective Prescribing and Therapeutics Division, in partnership with Northern Ireland and Republic of Ireland, in a successful bid for EU funding to test develop, implement and assess new integrated care pathways for polypharmacy, including pharmacogenomics. As part of this project, the RDS will be working with NHS Tayside to test extending the current polypharmacy RDS decision support in the Vision primary care electronic health record system to include pharmacogenomics decision support.

7. Implementation projects

We have just completed a series of three workshops consulting on proposed improvements to the Being a partner in my care: Realistic Medicine together app, following piloting on 10 sites in late 2024. This app has been commissioned by Scottish Government Realistic Medicine to support patients and citizens to become active partners in shared decision-making and encouraging personalised care based on outcomes that matter to the person. We are keen to gather more feedback on this app. Please forward any feedback to ann.wales3@nhs.scot

 

 

Monitoring and Management of Suspected Fetal Growth Restriction (414)

Warning

Please report any inaccuracies or issues with this guideline using our online form

 

 

For the purposes of this guideline the following definitions apply:

Small for gestational age (SGA): Estimated fetal weight (EFW) or abdominal circumference (AC) <10th centile

Fetal growth restriction (FGR):  Where a fetus fails to reach its growth potential as adapted from the Delphi consensus:

Early Onset FGR <32wks

Late onset FGR ≥32wks

EFW or AC <3rd centile

Or Absent umbilical artery end diastolic flow (EDF)

Or EFW/AC <10th centile with at least one of:

  • Umbilical artery pulsatility index >95th centile or absent or reversed EDF
  • Uterine artery pulsatility index >95th centile

EFW <3rd centile

Or At least two of the following:

  • EFW <10th centile
  • EFW crossing ≥50 centiles
  • Umbilical artery pulsatility index >95th centile or absent or reversed EDF

This guideline does not apply to multiple pregnancies or babies with congenital abnormalities.

Estimated fetal weight should be used after 22+0wks as plotted on the Intergrowth chart on Badgernet. Prior to 22+0wks abdominal circumference should be used.

Babies found to have an AC <3rd centile at the time of routine anomaly scan should be referred to a fetal medicine specialist within the unit. Serological screening for cytomegalovirus and toxoplasmosis should be offered along with invasive testing for full karyotype and microarray.

The purpose of monitoring is to identify those babies suspected to have FGR and therefore at greater risk of adverse perinatal outcome. Birth timing balances risk of stillbirth against risk of prematurity including adverse outcomes associated with early term birth (37+0 - 38+6wks).

For babies identified as SGA with no features of FGR suitable surveillance is ultrasound every 2wks for biometry, umbilical artery doppler and liqor volume. In the absence of fetal or maternal compromise birth should be offered at 39+0wks. Examples of fetal or maternal compromise include hypertension, reduced fetal movements, reduced liqor volume or abnormal CTG.

For babies identified as early onset FGR, fetal biometry should be performed every 2wks with weekly liqor volume and umbilical artery doppler. If there is absent or reversed EDF prior to 32+0wks then twice weekly doppler should be performed and birth is indicated if the ductus venosus a wave is absent or reversed.

Cardiotocograph (CTG) can be performed from 26+0wks. If computerised CTG is available then short term variability (STV) should be used to guide birth timing. STV <2.6ms between 26+0 and 28+6wks or <3.0ms between 29+0 and 31+6wks indicates birth should be offered as does the presence of persistent unprovoked decelerations at any gestation. Frequency of CTG monitoring will be determined by the individual circumstances.

For babies identified as late onset FGR, fetal biometry should be performed every 2wks with weekly liqor volume and umbilical artery doppler. Middle cerebral artery doppler performed after 34wks gestation may guide timing of birth but further evidence is awaited on this.  

Frequency of CTG monitoring will depend on individual circumstances. If computerised CTG is available then birth is indicated if STV is <3.5ms between 32+0 and 33+6 or < 4.5ms at gestations >34wks, or in the presence of persistent unprovoked decelerations at any time.

Birth is indicated between 32+0 and 33+6wks if the umbilical artery EDF is reversed. Birth >34wks is indicated if umbilical artery EDF is absent or reversed. Early birth may also be indicated by other evidence of fetal compromise such as decreased liqor volume, maternal hypertension or reduced fetal movements.

If monitoring is reassuring then birth can be offered at 37wks for babies with suspected FGR.

A proportion of babies who are growth restricted will not be SGA, particularly those presenting late in the third trimester.

Evidence of reduced growth velocity or “tailing growth”  is defined as a drop of 50 centiles  on sequential scanning for example a drop from the 70th to the 20th percentile. This should prompt further ultrasound in two weeks with birth offered at 37wks, earlier if there is evidence of fetal or maternal compromise as outlined above. If EFW falls below 10th centile or there are abnormal dopplers then ongoing monitoring and birth timing is as for late onset FGR babies.

Algorithm for the monitoring and management of fetal growth restriction

Editorial Information

Last reviewed: 27/02/2024

Next review date: 08/02/2027

Author(s): Roseanna Metcalfe.

Version: 2

Approved By: Maternity Clinical Governance Group

Document Id: 414

Evidence method

Adapted from Saving Baby’s Lives Care Bundle V 3 (2023) and the ISUOG Practice Guideline on diagnosis and management of SGA fetus and FGR (2020)